Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

agalsidase beta (Fabrazyme)

agalsidase beta is an FDA-licensed reference biologic from Genzyme Corporation.

351(a) biologicBLA 103979 Genzyme Corporation
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2003

Reference product

Originator biologic
351(a)BLA 103979

Fabrazyme agalsidase beta

Genzyme Corporation

View full reference-product record
Approved
Marketing
Rx
Center
CDER
Patents
None listed

Molecular structure

RCSB Protein Data Bank

Experimental 3D structure for agalsidase beta from the RCSB Protein Data Bank (PDB 1R47).

3D molecular structure of agalsidase beta (PDB entry 1R47)

Interactive biological assembly from PDB entry 1R47. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.

Exclusivity & patent cliffs

Protection horizon
  1. Reference approval

    Approval date of the reference agalsidase beta product.

    23 yr 9 mo ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    in 1 yr 6 mo

agalsidase beta: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for agalsidase beta.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.